- Open Access
Design, synthesis, and molecular docking studies of diphenylquinoxaline-6-carbohydrazide hybrids as potent α-glucosidase inhibitors
BMC Chemistry volume 16, Article number: 57 (2022)
A novel series of diphenylquinoxaline-6-carbohydrazide hybrids 7a–o were rationally designed and synthesized as anti-diabetic agents. All synthesized compounds 7a–o were screened as possible α-glucosidase inhibitors and exhibited good inhibitory activity with IC50 values in the range of 110.6 ± 6.0 to 453.0 ± 4.7 µM in comparison with acarbose as the positive control (750.0 ± 10.5 µM). An exception in this trend came back to a compound 7k with IC50 value > 750 µM. Furthermore, the most potent derivative 7e bearing 3-fluorophenyl moiety was further explored by kinetic studies and showed the competitive type of inhibition. Additionally, the molecular docking of all derivatives was performed to get an insight into the binding mode of these derivatives within the active site of the enzyme. In silico assessments exhibited that 7e was well occupied in the binding pocket of the enzyme through favorable interactions with residues, correlating to the experimental results.
Diabetes mellitus (DM) can be construed as a chronic metabolic disorder identified by insistent hyperglycemia [1,2,3]. It can also be taken into consideration as the ailment of protein, fat, and carbohydrate metabolism resulting from failure in insulin secretion (type I diabetes), insulin dysfunction (type II diabetes), or both [4, 5]. Hyperglycemia, as the most stringent criterion of all types of diabetes, causes significant complications, including lipid metabolism disorders, kidney failure, neuropathy, and cardiovascular disorders . Conducted by the International Diabetes Federation (IDF 2021), it was revealed that 537 million adults are globally afflicted with DM, and this number will increase dramatically to around 643 million by 2030 if no practical solution is discovered. There are several guidelines recommended for normalization of the blood glucose level, including controlled diet as well as physical exercise, which can be useful against a sedentary lifestyle . Along the same line, to manage and control type II diabetes, one therapeutic way is to inhibit enzymes that convert carbohydrates into glucose [8,9,10].
In this regard, α-glucosidase is one of the most important enzyme found in the digestive system [11, 12]. The α-glucosidase presented on the brush border of human intestinal mucosal cells participates in the body's carbohydrate metabolism to convert oligosaccharides and disaccharides into monosaccharides by hydrolyzing the α-1,4-glycosidic bond [13,14,15]. Acarbose as a potent pseudo carbohydrate inhibitor of α-glucosidase and a-amylase reduces the breakdown of complex carbohydrates into monosaccharides such as glucose [16, 17]. However, long-term use may result in mild-to-moderate gastrointestinal side effects, flatulence, and diarrhea . Other drugs such as biguanides (metformin), meglitinides, sulfonylureas, and thiazolidinediones are used as oral drugs to treat type II DM still associated with mentioned adverse side effects [19, 20]. Moreover, it is well documented that taking advantage of the other commercially available therapies controls only 36% of type II DM patients to achieve glycemic control . As a result, the need for novel and safe α-glucosidase inhibitors to control the blood sugar level is critical [22,23,24,25].
Quinoxaline, also called benzo[b][1,4]diazine or benzopyrazine, and its derivatives are an integral part of medicinal chemistry owing to their wide range of biological activity, including antithrombotic, anti-tubercular, antitumor, antimalarial, antiplasmodial, antiprotozoal, AMPA receptor antagonist, and antiviral activities [26,27,28,29,30,31]. Besides, recent extensive studies have reported novel quinoxaline-based derivatives with high anti-α-glucosidase inhibitory potencies [32, 33].
Acyl hydrazone moiety has been known as a privileged structure in drug discovery due to its easy synthetic procedure via condensation of hydrazides and aldehydes or ketones under acid, base catalysis, or microwave irradiation . This unique pharmacophore can participate in several interactions with the proposed targets through both hydrogen-bond acceptor and donor of amino-acid residues of enzyme binding site. Acylhydrazone exhibited a wide range of pharmacological potencies as antimicrobial , anticancer , analgesic , and anti-inflammatory(38) agents. Also, the potencies of acylhydrazone derivatives as tyrosinase [39, 40], acetylcholinesterase , BACE1 , and α-glucosidase  inhibitors were reported. Along the same line, Schiff bases are among the essential organic moiety with diverse biological activities such as urease, α-glucosidase, and β-glucuronidase inhibitory activities [44,45,46,47,48,49].
In the current study, novel biphenylquinoxaline derivatives bearing different acyl hydrazone were designed, synthesized, and evaluated against the α-glucosidase. The most potent compound was then subjected to kinetic study and molecular docking assessments.
Results and discussion
There are a bunch of reports in the literature in which both quinoxaline and hydrazide–hydrazone scaffolds have shown potent α-glucosidase inhibitory activity. Take the example of the recent research, compound A (Fig. 1) containing both mentioned moieties exerted an IC50 value of 21.92 μg mL−1 in comparison with the standard acarbose (IC50 = 22.32 μg mL−1) as an effective α-glucosidase inhibitor . In another similar research, compound B (IC50 = 22.67 ± 0.1 μmol mL−1 compared with the standard acarbose 38.25 ± 0.1 μmol mL−1) proved the potent effect of quinoxaline and acyl hydrazone moieties as the α-glucosidase inhibitor . Moreover, concrete evidence supports that the compounds bearing each of these two scaffolds showed potent α-glucosidase inhibitory activity. In this context, compound C bearing quinoxaline ring with IC50 value of 83.78 ± 0.89 μmol mL−1 in comparison with the standard acarbose 72.58 ± 0.682 μmol mL−1  and compound D with IC50 value of 83.78 ± 0.89 μmol mL−1 compared with the standard acarbose 72.58 ± 0.682 μmol mL−1 bearing hydrazide–hydrazone scaffold are good examples .
With this information in hand; herein, a series of diphenylquinoxaline-6-carbohydrazide hybrids as the novel agents against α-glucosidase were designed and synthesized. All derivatives were evaluated as α-glucosidase inhibitors in vitro and the most potent derivative in this group was subjected to a kinetic study to determine the type of inhibition. In addition, molecular docking studies of all derivatives were performed to get insight into the binding affinity and pose of these compounds within the enzyme binding site.
Scheme 1 represents the pathway for the synthesis of diphenylquinoxaline-6-carbohydrazide hybrids 7a–o. As can be seen in this scheme, 2,3-diphenylquinoxaline-6-carboxylic acid 3 was synthesized through a reaction between commercial benzil 1 and 3,4-diaminobenzoic acid 2 in acetic acid as a solvent in 50 °C. Then, the mentioned product 3 experienced an esterification reaction with dry ethanol as the solvent and reagent in the presence of a catalytic amount of sulfuric acid. Later on, the reaction of ethyl 2,3-diphenylquinoxaline-6-carboxylate 4 with hydrazine 8 resulted in the formation of 2,3-diphenylquinoxaline-6-carbohydrazide 5 at room temperature. Finally, the reaction between the latter compound (5) and a wide range of aldehydes 6a-o led to the formation of the final products 7a–o. The latter derivatives (7a-o) were fully characterized by 1H NMR, 13C NMR, FT-IR, and elemental analysis.
α-glucosidase inhibitory activity
In this project, which is aimed to develop new α-glucosidase inhibitors, all aromatic carbohydrazide derivatives 7a–o were screened. The synthetic compounds showed a varying degree of α-glucosidase inhibition with IC50 values in the range of 110.6 to more than 750 µM (Table 1).
According to the results of the investigation, 7a being phenyl moiety exhibited an IC50 value of 154.8 ± 3.0 µM. Next, the effect of compounds with electron-withdrawing groups was investigated, and it was shown that the presence of all of the electron-withdrawing groups (except fluorine) caused a decrease in inhibitory potencies. In detail, the appearance of the nitrophenyl group at the ortho position (7b) had the least negative impact on the inhibition, followed by 7d (R = 4–NO2–C6H4) ˃ 7c (R = 3–NO2–C6H4). This order of potency could attribute to both the power of inductive and resonance effects of these moieties in the mentioned position.
Compound 7f bearing chlorophenyl substitution (as an electron-withdrawing group) at para position showed less inhibitory effect than 7d (in which the nitro moiety is in para position). The reason can be ascribed to the differences in electronegativity of the mentioned substitutions. Among all electron-withdrawing groups, just compound 7e possessing fluorophenyl substituent at the meta-position was found to show potent inhibitory activity which could be due to electron-withdrawing potencies as well equality in size with H- substituent (7a). 7 g derivative bearing para-methoxyphenyl substituent as electron-donating groups showed an IC50 value of 305 µM, which was a higher value than 7a as unsubstituted derivative as well as all electron-withdrawing substituted compounds.
Also, the presence of multi-substitution groups (7h, 7i, 7j, 7k) caused a destructive effect on α-glucosidase inhibition compared to unsubstituted derivative (7a).
Further, the effect of ring replacements was also evaluated. Results disclosed that bulky ring substitutions such as phenoxy phenyl (7l), 5-nitrobenzodioxole (7m), and naphthyl (7n) reduced the inhibitory activity significantly compared to phenyl counterpart (7a). Noteworthy, the replacement of phenyl ring with thiophene moiety 7o, as a classical bioisostere of phenyl, slightly improved the α-glucosidase inhibition. The comparative betterment achieved in the effect of thiophene moiety can be referred to as the more lipophilicity of thiophene in comparison with phenyl moiety.
Overall, the presence of one substituent on the phenyl, whether electron-withdrawing or donating groups (compounds 7b-g) or even multi-substitutions, resulted in a relative decrease in acquired effects. Also, the presence of bulky rings showed a further negative impact on pharmacological activity. It seems that the pocket of the receptor has limited space to bind to the derivatives and regarding that, the backbone of the designed structure is bulky and spacious, the presence of small substitutions such as phenyl, fluorophenyl and thiophene moieties are more favorable.
Enzyme kinetic studies
According to Fig. 2A, the Lineweaver–Burk plot showed that the Km gradually increased and Vmax remained unchanged with increasing inhibitor concentration indicating a competitive inhibition. The results show sample 7e bind to the active site on the enzyme and compete with the substrate for binding to the active site. Furthermore, the plot of the Km versus different concentrations of inhibitor gave an estimate of the inhibition constant, Ki of 107 µM (Fig. 2B).
Next, the molecular docking studies of all derivatives were performed. In the first step, to properly predict the binding pose of derivatives within the active site, the redocking process of acarbose (as a crystallographic ligand) with human lysosomal acid-alpha-glucosidase was performed using induce fit docking of the Schrodinger package. Alignment of the best pose of acarbose in the active site of α-glucosidase and crystallographic ligand recorded an RMSD value of 1.73 Å (Fig. 3).
Next, the same procedure was then applied for the docking of all derivatives, and the results are summarized in Table 2. The molecular docking study showed the binding energy of acarbose as a native ligand was − 6.143 kcal/mol while the glide score value of 7a –o ranges from − 2.207 to − 5.802 kcal/mol. As can be seen the most potent derivative in in vitro assay was 7e (IC50 = 110.6 ± 6.0 µM) > 7o (IC50 = 145.4 ± 5.0 µM) > 7a (IC50 = 154.8 ± 3.0 µM) > 7b (IC50 = 175.0 ± 5.9 µM) exhibited the best in silico results with docking score value of − 5.802, − 5.493, − 5.690 and − 5.520 kcal/mol, respectively. Similarly, the least active derivatives 7k demonstrated the worse result with a dock value of -2.207 kcal/mol. The violation of IC50 values and in silico results came back to 7h (R = 2–NO2–3–OMe–C6H3) with moderate inhibition (IC50 = 305.5 ± 7.2) and a good glide score value.
3D interaction pattern of 7e (Fig. 4) showed quinoxaline ring made one hydrogen bound interaction with Trp481 and two pi-pi stacked interactions with Trp481 and Phe525, respectively. Phenyl ring also recorded aromatic H-bound interaction with Asp616 and Asp404. However, the 3D interaction pattern of 7k (inactive derivative) exhibited interesting results so the presence of three methoxy groups changes the orientation of the molecular within the binding pocket so that it cannot fit into the binding site and can not participate in critical interaction with the enzyme (Fig. 5).
In conclusion, a novel series of diphenylquinoxaline-6-carbohydrazide hybrids 7a–o as the new anti-diabetic agents with α-glucosidase inhibitory potential were designed and synthesized. These novel compounds exhibited good α-glucosidase inhibitory activity with IC50 values in the range of 110.6 ± 6.0 to ˃750 µM in comparison with acarbose (IC50 = 750.0 ± 10.5 µM) as the positive control. Compound 7e, as the most potent derivative, was further investigated, and the kinetic studies showed that the type of inhibition for compound 7e is competitive, which means it competed with the substrate to attach to the active site of the enzyme. Molecular docking studies of 7e within the α-glucosidase active site demonstrated that this molecule fitted well into the α-glucosidase binding pocket and showed hydrogen, aromatic hydrogen bond interactions. Thus, the derivatives appear to be an ideal candidate for initiating lead anti-DM drug discovery.
The measured data on melting points were evaluated on a Kofler hot stage apparatus and were uncorrected for most derivatives. The NMR (1H and 13C) and IR spectra were gained by employing Bruker 300-NMR and ALPHA FT-IR spectrometer on KBr disks, respectively. The chemical reagents were obtained from Aldrich and Merck as well. Elemental analyses were also performed on an Elementar Analysensystem GmbH VarioEL CHNS mode. Moreover, the Spectroscopic data of final products, including 1H and 13C NMR, are available in the supporting information.
General procedure for the synthesis of 2,3-diphenylquinoxaline-6-carboxylic acid 3
The mixture of equivalent amounts of benzil 1 (5 mmol, 1.05 g) and 3,4-diaminobenzoic acid 2 (5 mmol, 0.76 g) was stirred in glacial acetic acid (20 ml) at 50 °C for 4–8 h. After completion of the reaction (monitored by the TLC), the participated product 3 was filtrated and purified by ethanol or ethyl acetate[42, 50].
General procedure for the synthesis of ethyl 2,3-diphenylquinoxaline-6-carboxylate 4
The 2,3‐diphenylquinoxaline-6-carboxylic acid 3 (5 mmol) was poured in dry ethanol (20 ml), and H2SO4 was added to the medium. The mixture was refluxed for 12 h, and the white solid of the desired product 4 was filtered off after pouring the mixture into the water.
General procedure for the synthesis of 2,3-diphenylquinoxaline-6-carbohydrazide 5.
The mixture of 2,3-diphenylquinoxaline-6-carboxylate 4 (5 mmol, 1.05 g) and hydrazine (15 ml) was stirred in ethanol (20 ml) at the ambient temperature for 16 h. After completion of the reaction (monitored by the TLC), the participated product 5 was filtrated and purified by ethanol or ethyl acetate.
General procedure for the synthesis of diphenylquinoxaline-2-carbohydrazide derivatives 7a–o
A mixture of 2,3-diphenylquinoxaline-6-carbohydrazide 5 (1 mmol) and appropriate benzaldehydes (6a–o) (1 mmol) in the presence of a catalytic amount of para-toluenesulfonic acid (PTSA) in ethanol was stirred at room temperature for 1 h. Then, the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and the solvent was evaporated. The residue was purified by column chromatography to give the final products (7a–o) (Additional file 1).
White solid. Yield: 77%. Mp 230–232 °C; IR (KBr): υ (cm−1) = 3213, 3058, 1677, 1555. 1H NMR (301 MHz, DMSO-d6) δ 12.18 (s, 1H), 8.79 (d, J = 1.8 Hz, 1H), 8.53 (s, 1H), 8.33 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 7.7 Hz, 2H), 7.52 – 7.40 (m, 5H), 7.40 – 7.32 (m, 5H), 7.27 (t, J = 7.7 Hz, 2H), 7.16 (t, J = 7.8 Hz, 1H). 13C NMR (76 MHz, DMSO-d6) δ 162.32, 154.77, 154.37, 148.93, 142.25, 140.48, 140.20, 138.96, 138.92, 134.79, 132.03, 130.25, 130.17, 129.90, 129.55, 129.46, 128.56, 127.66 ppm. Anal. calcd. For C28H20N4O: C, 78.49; H, 4.70; N, 13.08. Found: C, 78.41; H, 4.63; N, 13.16.
Pale yellow solid. Yield: 90%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3193, 3065, 1692, 1617, 1530. 1H NMR (301 MHz, DMSO-d6) δ 12.55 (s, 1H), 8.98 (s, 1H), 8.83 (s, 1H), 8.34 (d, J = 8.8 Hz, 1H), 8.27–8.13 (m, 2H), 8.09 (d, J = 8.2 Hz, 1H), 7.83 (t, J = 7.7 Hz, 1H), 7.68 (t, J = 7.8 Hz, 1H), 7.61 – 7.43 (m, 5H), 7.43 – 7.29 (m, 5H). 13C NMR (76 MHz, DMSO-d6) δ 162.51, 154.96, 154.47, 148.70, 144.00, 142.35, 140.16, 138.94, 138.91, 134.18, 131.21, 130.25, 130.17, 129.57, 129.49, 129.13, 128.90, 128.56, 128.40, 125.15 ppm. Anal. calcd. For C28H19N5O3: C, 71.03; H, 4.04; N, 14.79. Found C, 71.14; H, 3.96; N, 14.68.
Pale yellow solid. Yield: 91%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3196, 3071, 1696, 1613, 1523. 1H NMR (301 MHz, DMSO-d6) δ 12.45 (s, 1H), 8.79 (d, J = 1.9 Hz, 1H), 8.62 (s, 1H), 8.53 (s, 1H), 8.33 (dd, J = 8.6, 1.8 Hz, 1H), 8.27 – 8.18 (m, 2H), 8.15 (d, J = 7.8 Hz, 1H), 7.73 (t, J = 7.9 Hz, 1H), 7.56 – 7.48 (m, 5H), 7.46 – 7.34 (m, 5H). 13C NMR (76 MHz, DMSO-d6) δ 162.25, 155.11, 154.62, 150.91, 142.32, 141.45, 140.42, 140.14, 134.05, 132.22, 130.26, 130.11, 129.69, 129.58, 129.46, 129.26, 128.86, 128.85, 128.48, 127.17, 124.72 ppm. Anal. calcd. For C28H19N5O3: C, 71.03; H, 4.04; N, 14.79. Found C, 71.15; H, 4.12; N, 14.66.
Pale yellow solid. Yield: 92%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3194, 3074, 1691, 1616, 1529. 1H NMR (301 MHz, DMSO-d6) δ 12.45 (s, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.58 (s, 1H), 8.31 (dd, J = 8.6, 1.8 Hz, 1H), 8.27 – 8.17 (m, 3H), 7.96 (d, J = 8.4 Hz, 2H), 7.56 – 7.44 (m, 5H), 7.43 – 7.33 (m, 5H). 13C NMR (76 MHz, DMSO-d6) δ 161.45, 154.75, 154.34, 148.82, 142.21, 140.30, 138.90, 134.86, 134.28, 130.14, 129.53, 129.41, 129.39, 129.25, 128.50, 127.32, 126.06, 124.93 ppm. Anal. calcd. For C28H19N5O3: C, 71.03; H, 4.04; N, 14.79. Found C, 71.12; H, 4.08; N, 14.72.
White solid. Yield: 84%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3228, 3073, 1711, 1557, 1248. 1H NMR (301 MHz, DMSO-d6) δ 12.31 (s, 1H), 8.78 (s, 1H), 8.54 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 8.18 (d, J = 8.6 Hz, 1H), 7.61 – 7.40 (m, 8H), 7.39 – 7.28 (m, 5H), 7.24 (td, J = 8.5, 2.7 Hz, 1H). 13C NMR (76 MHz, DMSO-d6) δ 162.84 (JC–F = 245.2 Hz), 162.43, 154.78, 154.33, 147.39 (JC–F = 2.2 Hz), 142.27, 140.14, 138.93, 138.89, 137.27 (JC–F = 7.9 Hz), 134.42, 131.31 (JC–F = 7.4 Hz), 130.24, 130.16, 129.53, 128.79, 128.53, 124.03 (JC–F = 1.6 Hz), 117.31 (JC–F = 21.5 Hz), 113.48 (JC–F = 22.7 Hz) ppm. Anal. calcd. For C28H19FN4O: C, 75.32; H, 4.29; N, 12.55. Found: C, 75.39; H, 4.06; N, 12.61.
White solid. Yield: 90%. Mp 234–238 °C; IR (KBr): υ (cm−1) = 3422, 1781, 1688, 720. 1H NMR (301 MHz, DMSO-d6) δ 12.30 (s, 1H), 8.79 (d, J = 1.9 Hz, 1H), 8.54 (s, 1H), 8.34 (d, J = 8.8 Hz, 1H), 8.26 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.58 – 7.42 (m, 7H), 7.42 – 7.31 (m, 5H). 13C NMR (76 MHz, DMSO-d6) δ 162.50, 154.96, 154.52, 147.58, 144.14, 142.30, 140.18, 138.95, 138.91, 135.15, 134.65, 133.64, 130.25, 130.17, 129.44, 129.31, 128.76, 128.60 ppm. Anal. calcd. For C28H19ClN4O: C, 72.65; H, 4.14; N, 12.10. Found: C, 72.53; H, 3.97, 12.27.
N'-(4-methoxybenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide 7 g
White solid. Yield: 81%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3199, 3054, 1697, 1550. 1H NMR (301 MHz, DMSO-d6) δ 12.11 (s, 1H), 8.78 (s, 1H), 8.51 (s, 1H), 8.32 (dd, J = 8.5, 1.8 Hz, 1H), 8.21 (d, J = 8.5 Hz, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.56 – 7.40 (m, 5H), 7.39 – 7.27 (m, 5H), 7.01 (d, J = 8.3 Hz, 2H), 3.59 (s, 3H). 13C NMR (76 MHz, DMSO-d6) δ 162.24, 161.39, 154.73, 154.34, 148.81, 142.20, 140.19, 138.96, 138.92, 134.86, 130.24, 130.16, 129.52, 129.45, 129.29, 128.55, 127.27, 114.77, 55.74 ppm. Anal. calcd. For C29H22N4O2: C, 75.97; H, 4.84; N, 12.22. Found: C, 76.11; H, 4.73; N, 12.16.
Pale yellow solid. Yield: 86%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3191, 3032, 1707, 1586, 1515. 1H NMR (301 MHz, DMSO-d6) δ 12.42 (s, 1H), 8.79 (d, J = 1.9 Hz, 1H), 8.48 (s, 1H), 8.33 (dd, J = 8.7, 1.8 Hz, 1H), 8.23 (d, J = 8.7 Hz, 1H), 7.71 – 7.60 (m, 2H), 7.56 – 7.47 (m, 5H), 7.47 – 7.31 (m, 6H), 3.94 (s, 3H). 13C NMR (76 MHz, DMSO-d6) δ 162.31, 155.01, 154.53, 150.86, 142.38, 141.55, 140.38, 140.15, 138.94, 138.90, 134.09, 132.27, 130.25, 130.17, 129.50, 129.32, 128.83, 128.57, 127.12, 118.69, 57.30 ppm. Anal. calcd. For C29H21N5O4: C, 69.18; H, 4.20; N, 13.91. Found: C, 69.29; H, 4.28; N, 13.80.
Pale yellow solid. Yield: 88%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3192, 3039, 1711, 1593, 1521. 1H NMR (301 MHz, DMSO-d6) δ 11.89 (s, 1H), 8.77 (s, 1H), 8.51 (s, 1H), 7.44 – 7.41 (m, 2H), 8.22 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 7.3 Hz, 1H), 7.85 – 7.82 (m, 4H), 7.73 (d, J = 7.3 Hz, 1H), 7.42 – 7.34 (m, 6H). 13C NMR (76 MHz, DMSO-d6) δ 164.03, 154.90, 154.31, 148.52, 143.95, 142.15, 140.07, 139.99, 138.78, 134.14, 131.21, 130.26, 130.15, 129.61, 129.57, 129.41, 129.13, 128.90, 128.56, 128.32, 125.12, 124.15 ppm. Anal. calcd. For C28H18ClN5O3: C, 66.21; H, 3.57; N, 13.79. Found: C, 66.09; H, 3.42; N, 13.91.
White solid. Yield: 73%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3232, 3073, 1696, 1579, 1288. 1H NMR (301 MHz, DMSO-d6) δ 12.12 (s, 1H), 9.72 (s, 1H), 8.70 (s, 1H), 8.46 (s, 1H), 8.26 (d, J = 8.8 Hz, 1H), 8.09 (d, J = 8.7 Hz, 1H), 7.51 – 7.36 (m, 5H), 7.35 – 7.20 (m, 6H), 7.10 (d, J = 8.1 Hz, 1H), 6.88 (d, J = 8.0 Hz, 1H), 3.83 (s, 3H). 13C NMR (76 MHz, DMSO-d6) δ 162.51, 154.54, 154.10, 150.51, 149.66, 148.55, 142.12, 140.10, 138.81, 138.79, 134.66, 130.19, 130.09, 129.39, 128.56, 128.44, 126.09, 123.10, 115.83, 109.31, 55.98 ppm. Anal. calcd. For C29H22N4O3: C, 73.40; H, 4.67; N, 11.81. Found: C, 73.48; H, 4.56; N, 11.84.
White solid. Yield: 70%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3298, 3207, 3065, 1660, 1605. 1H NMR (301 MHz, DMSO-d6) δ 12.24 (s, 1H), 8.76 (s, 1H), 8.49 (s, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.19 (d, J = 8.7 Hz, 1H), 7.56 – 7.41 (m, 5H), 7.40 – 7.29 (m, 5H), 7.06 (s, 2H), 3.84 (s, 6H), 3.72 (s, 3H). 13C NMR (76 MHz, DMSO-d6) δ 162.51, 154.74, 154.32, 153.64, 148.96, 142.23, 140.14, 139.81, 138.91, 138.89, 134.71, 130.22, 130.14, 129.53, 129.45, 128.69, 128.52, 104.88, 60.57, 56.37 ppm. Anal. calcd. For C31H26N4O4: C, 71.80; H, 5.05; N, 10.80. Found: C, 71.69; H, 5.19; N, 10.77.
N'-(3-phenoxybenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide 7 l
White solid. Yield: 73%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3230, 3063, 1711, 1568. 1H NMR (301 MHz, DMSO-d6) δ 12.27 (s, 1H), 8.79 (d, J = 1.8 Hz, 1H), 8.55 (s, 1H), 8.33 (dd, J = 8.8, 1.9 Hz, 1H), 8.25 (d, J = 8.7 Hz, 1H), 7.57 – 7.46 (m, 5H), 7.45 – 7.32 (m, 10H), 7.21 (d, J = 7.4 Hz, 1H), 7.19 – 7.04 (m, 3H). 13C NMR (76 MHz, DMSO-d6) δ 162.45, 157.77, 156.77, 154.91, 154.48, 148.20, 142.30, 140.18, 138.96, 138.92, 136.74, 134.64, 131.05, 130.67, 130.25, 130.18, 129.64, 129.50, 128.76, 128.59, 124.33, 123.36, 119.47, 116.26 ppm. Anal. calcd. For C34H24N4O2: C, 78.44; H, 4.65; N, 10.76. Found: C, 78.39; H, 4.81; N, 10.83.
N'-((6-nitrobenzo[d][1,3]dioxol-5-yl)methylene)-2,3-diphenylquinoxaline-6-carbohydrazide 7 m
Pale yellow solid. Yield: 89%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3214, 3077, 1688, 1565, 1522. 1H NMR (301 MHz, DMSO-d6) δ 12.23 (s, 1H), 8.76 (s, 1H), 8.48 (s, 1H), 8.30 (d, J = 8.9 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.01 (s, 1H), 7.51 – 7.44 (m, 5H), 7.40 – 7.29 (m, 5H), 7.16 (s, 1H), 5.97 (s, 2H). 13C NMR (76 MHz, DMSO-d6) δ 162.66, 158.76, 158.17, 154.57, 153.68, 149.49, 148.25, 142.12, 140.10, 138.38, 134.19, 130.19, 130.09, 129.39, 128.44, 127.92, 125.50, 122.49, 115.93, 110.85, 100.65 ppm. Anal. calcd. For C29H19N5O5: C, 67.31; H, 3.70; N, 13.53. Found: C, 67.24; H, 3.79; N, 13.49.
White solid. Yield: 77%. Mp > 250 °C; IR (KBr): υ (cm−1) = 3196, 3059, 1695, 1558. 1H NMR (301 MHz, DMSO-d6) δ 12.30 (s, 1H), 9.24 (s, 1H), 8.92 (d, J = 8.6 Hz, 1H), 8.86 (s, 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.21 (d, J = 8.8 Hz, 1H), 8.05 – 7.88 (m, 3H), 7.67 (t, J = 7.7 Hz, 1H), 7.57 (t, J = 7.7 Hz, 2H), 7.52 – 7.41 (m, 5H), 7.40 – 7.29 (m, 5H). 13C NMR (76 MHz, DMSO-d6) δ 162.27, 154.76, 154.33, 148.74, 142.28, 140.21, 138.95, 138.92, 134.60, 133.99, 131.11, 130.76, 130.27, 130.19, 129.96, 129.60, 129.45, 129.25, 128.53, 128.27, 127.76, 126.69, 125.96, 124.68 ppm. Anal. calcd. For C32H22N4O: C, 80.32; H, 4.63; N, 11.71. Found: C, 80.25; H, 4.76; N, 11.58.
White solid. Yield: 84%. Mp 242–246 °C; IR (KBr): υ (cm−1) = 3228, 3053, 1715, 1588. 1H NMR (301 MHz, DMSO-d6) δ 12.20 (s, 1H), 8.79 (s, 1H), 8.77 (s, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.70 (d, J = 5.0 Hz, 1H), 7.54 – 7.44 (m, 5H), 7.43 – 7.30 (m, 6H), 7.15 (t, J = 4.4 Hz, 1H). 13C NMR (76 MHz, DMSO-d6) δ 162.26, 154.78, 154.37, 143.98, 142.25, 140.17, 139.54, 138.93, 138.90, 134.66, 131.66, 130.25, 130.17, 129.58, 129.45, 129.33, 128.54, 128.34 ppm. Anal. calcd. For C26H18N4OS: C, 71.87; H, 4.18; N, 12.89. Found: C, 71.81; H, 4.12; N, 12.96.
α-glucosidase inhibition assay
The α-glucosidase inhibitory effects of diphenylquinoxaline-6-carbohydrazide hybrids 7a–o were determined by previously reported method . In this protocol, 20 μL of enzyme solution (α-glucosidase from Saccharomyces cerevisiae, EC188.8.131.52, 20 U/mg), 20 μL of test compounds 7a–o with various concentrations, and 135 μL of potassium phosphate buffer were added and incubated in the 96-well plate for 10 min at 37 ◦C. Later on, 25 μL of the substrate (p-nitrophenyl glucopyranoside, 4 mM) was added to each well of the plate, and incubation was continued for 20 min at 37 ◦C. Next, absorbance was measured at 405 nm by spectrophotometer (Gen5, Power wave xs2, BioTek, USA), and the IC50 value for each tested compound was calculated by taking advantage of the nonlinear regression curve [52, 53].
Enzyme kinetic studies
The mode of inhibition of the most active compound (7e), identified with the lowest IC50, was investigated against an α-glucosidase activity with different concentrations of p-nitrophenyl α -D-glucopyranoside (2–10 mM) as substrate in the absence and presence of sample 7e at different concentrations (0, 30, 70 and 110 µM). A Lineweaver–Burk plot was generated to identify the type of inhibition and the Michaelis–Menten constant (Km) value was determined from the plot between reciprocal of the substrate concentration (1/[S]) and reciprocal of enzyme rate (1/V) over various inhibitor concentrations. The experimental inhibitor constant (Ki) value was constructed by secondary plots of the inhibitor concentration [I] versus Km [43, 54].
The molecular docking investigation of all derivatives were performed using the maestro molecular modeling platform (version 10.5), Schrödinger suites . X-ray crystallographic structure of α-glucosidase 5NN8 was downloaded from the PDB website (https://www.rcsb.org/) . A protein preparation wizard was used to remove water molecules and co-crystallized atoms from the protein and prepare the receptor. Moreover, heteroatom states were generated at pH: 7.4 by EPIK, and H-bonds were assigned using PROPKA at the same pH. 2D structure of ligands was drawn in Hyperchem, energy minimized using, molecular mechanics and molecular quantum approaches. Next, the ligand preparation wizard was used to prepare the ligand using the OPLS_2005 force field . Acarbose all compounds were docked into the binding sites using glide tasked to report five poses per ligand with flexible ligand sampling and extra precision [17, 43].
Availability of data and materials
The datasets generated and/or analysed during the current study are available in the Worldwide Protein Data Bank (wwPDB) repository. (http://www.rcsb.org).
Vijayaraghavan K, Iyyam Pillai S, Subramanian SP. Design, synthesis and characterization of zinc-3 hydroxy flavone, a novel zinc metallo complex for the treatment of experimental diabetes in rats. Eur J Pharmacol. 2012;680(1–3):122–9.
Somtimuang C, Olatunji OJ, Ovatlarnporn C. Evaluation of in vitro α-amylase and α-glucosidase inhibitory potentials of 14 medicinal plants constituted in Thai folk antidiabetic formularies. Chem Biodivers. 2018;15(4): e1800025.
Zeng B, Chen K, Du P, Wang SS, Ren B, Ren YL, et al. Phenolic compounds from clinopodium Chinense (Benth.) O. Kuntze and their inhibitory effects on α-glucosidase and vascular endothelial cells injury. Chem Biodivers. 2016;13(5):596–601.
Wali H, Anwar A, Shamim S, Khan KM, Mahdavi M, Salar U, et al. Synthesis, in vitro, and in silico studies of newly functionalized quinazolinone analogs for the identification of potent α-glucosidase inhibitors. J Iran Chem Soc. 2021;18(8):2017–34.
Zhang Y, Luo L, Li Z, Li H, Yao X. Anti-lipid peroxidation, α-glucosidase and α-amylase inhibitory effects of the extract of capitula of coreopsis tinctoria nutt. and protection effects on high-fat/high-sugar and streptozotocin-induced type 2 diabetes in mice. Chem Biodivers. 2019;16(12):e1900514.
Hossain U, Das AK, Ghosh S, Sil PC. An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2020;145: 111738.
Tang Y-Z, Wang G, Jiang Z-H, Yan T-T, Chen Y-J, Yang M, et al. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Diabetol Metab Syndr. 2015;7(1):1–9.
Heacock PM, Hertzler SR, Williams JA, Wolf BW. Effects of a medical food containing an herbal α-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults. J Am Diet Assoc. 2005;105(1):65–71.
Kim S-D. α-Glucosidase inhibitor from Buthus martensi Karsch. Food Chem. 2013;136(2):297–300.
Jong-Anurakkun N, Bhandari MR, Kawabata J. α-glucosidase inhibitors from Devil tree (Alstonia scholaris). Food Chem. 2007;103(4):1319–23.
Chiba S. Molecular mechanism in α-glucosidase and glucoamylase. Biosci Biotechnol Biochem. 1997;61(8):1233–9.
Sohrabi M, Binaeizadeh MR, Iraji A, Larijani B, Saeedi M, Mahdavi M. A review on α-glucosidase inhibitory activity of first row transition metal complexes: a futuristic strategy for treatment of type 2 diabetes. RSC Adv. 2022;12(19):12011–52.
Gong L, Feng D, Wang T, Ren Y, Liu Y, Wang J. Inhibitors of α-amylase and α-glucosidase: potential linkage for whole cereal foods on prevention of hyperglycemia. Food Sci Nutr. 2020;8(12):6320–37.
Ansari FL, Umbreen S, Hussain L, Makhmoor T, Nawaz SA, Lodhi MA, et al. Syntheses and biological activities of chalcone and 1, 5-benzothiazepine derivatives: promising new free-radical scavengers, and esterase, urease, and α-glucosidase inhibitors. Chem Biodivers. 2005;2(4):487–96.
Khan MS, Munawar MA, Ashraf M, Alam U, Ata A, Asiri AM, et al. Synthesis of novel indenoquinoxaline derivatives as potent α-glucosidase inhibitors. Bioorg Med Chem. 2014;22(3):1195–200.
Dodds SG, Parihar M, Javors M, Nie J, Musi N, Dave Sharp Z, et al. Acarbose improved survival for Apc+/Min mice. Aging Cell. 2020;19(2): e13088.
Moghaddam FM, Daneshfar M, Daneshfar Z, Iraji A, Samandari-Najafabad A, Faramarzi MA, et al. Synthesis and characterization of 1-amidino-O-alkylureas metal complexes as α-glucosidase Inhibitors: Structure-activity relationship, molecular docking, and kinetic studies. J Mol Struct. 2022;1250: 131726.
Dong Y, Zhang B, Sun W, Xing Y. Intervention of prediabetes by flavonoids from Oroxylum indicum. Bioactive food as dietary interventions for diabetes. Elsevier; 2019. p. 559–75.
DiNicolantonio JJ, Bhutani J, O’Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open heart. 2015;2(1): e000327.
Avery MA, Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA. Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61–74.
Miller BR, Nguyen H, Hu CJH, Lin C, Nguyen QT. New and emerging drugs and targets for type 2 diabetes: reviewing the evidence. Am Health Drug Benefits. 2014;7(8):452.
Avcı D, Altürk S, Sönmez F, Tamer Ö, Başoğlu A, Atalay Y, et al. Correction to: Novel metal complexes containing 6-methylpyridine-2-carboxylic acid as potent α-glucosidase inhibitor: synthesis, crystal structures, DFT calculations, and molecular docking. Mol Diversity. 2021. https://doi.org/10.1007/s11030-021-10299-z.
Siddiqui H, Baheej MAA, Ullah S, Rizvi F, Iqbal S, Haniffa HM, et al. Synthesis of 1,2,3, triazole modified analogues of hydrochlorothiazide via click chemistry approach and in-vitro α-glucosidase enzyme inhibition studies. Mol Diversity. 2021. https://doi.org/10.1007/s11030-021-10314-3.
Saeedi M, Raeisi-Nafchi M, Sobhani S, Mirfazli SS, Zardkanlou M, Mojtabavi S, et al. Synthesis of 4-alkylaminoimidazo[1,2-a]pyridines linked to carbamate moiety as potent α-glucosidase inhibitors. Mol Diversity. 2021;25(4):2399–409.
Peytam F, Adib M, Shourgeshty R, Mohammadi-Khanaposhtani M, Jahani M, Imanparast S, et al. Design and synthesis of new imidazo[1,2-b]pyrazole derivatives, in vitro α-glucosidase inhibition, kinetic and docking studies. Mol Diversity. 2020;24(1):69–80.
Ries UJ, Priepke HW, Hauel NH, Handschuh S, Mihm G, Stassen JM, et al. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents. Bioorg Med Chem Lett. 2003;13(14):2297–302.
Ancizu S, Moreno E, Solano B, Villar R, Burguete A, Torres E, et al. New 3-methylquinoxaline-2-carboxamide 1, 4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Bioorg Med Chem. 2010;18(7):2713–9.
Liu Z, Yu S, Di Chen GS, Wang Y, Hou L, Lin D, et al. Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2 (1H)-one derivatives as novel antitumor inhibitors of FGFR1. Drug Des Dev Ther. 2016;10:1489.
Rangisetty J, Gupta C, Prasad A, Srinivas P, Sridhar N, Parimoo P, et al. Synthesis of new arylaminoquinoxalines and their antimalarial activity in mice. J Pharm Pharmacol. 2001;53(10):1409–13.
Vicente E, Charnaud S, Bongard E, Villar R, Burguete A, Solano B, et al. Synthesis and antiplasmodial activity of 3-furyl and 3-thienylquinoxaline-2-carbonitrile 1, 4-di-N-oxide derivatives. Molecules (Basel, Switzerland). 2008;13(1):69–77.
Zarenezhad E, Farjam M, Iraji A. Synthesis and biological activity of pyrimidines-containing hybrids: focusing on pharmacological application. J Mol Struct. 2021;1230: 129833.
Settypalli T, Chunduri VR, Maddineni AK, Begari N, Allagadda R, Kotha P, et al. Design, synthesis, in silico docking studies and biological evaluation of novel quinoxaline-hydrazide hydrazone-1, 2, 3-triazole hybrids as α-glucosidase inhibitors and antioxidants. New J Chem. 2019;43(38):15435–52.
Shintre SA, Ramjugernath D, Islam MS, Mopuri R, Mocktar C, Koorbanally NA. Synthesis, in vitro antimicrobial, antioxidant, and antidiabetic activities of thiazolidine–quinoxaline derivatives with amino acid side chains. Med Chem Res. 2017;26(9):2141–51.
Maia RDC, Tesch R, Fraga CAM. Acylhydrazone derivatives: a patent review. Expert Opin Thera Pat. 2014;24(11):1161–70.
Yao X, Hu H, Wang S, Zhao W, Song M, Zhou Q. Synthesis, Antimicrobial activity, and molecular docking studies of aminoguanidine derivatives containing an acylhydrazone moiety. Iran J Pharm Res IJPR. 2021;20(2):536.
Zhang H, Min S, Zhang L, Li L. Design, synthesis and protein-binding character of an acylhydrazone anticancer candidate. J Mol Liq. 2022;348: 118034.
Mota FV, Coutinho FN, de Carvalho VMF, de Assis Correia JC, Bastos IVGA, Marcelino-Neto PP, et al. Antinociceptive effects of aza-bicyclic isoxazoline-acylhydrazone derivatives in different models of nociception in mice. Curr Top Med Chem. 2022;22(4):247–58.
Cerqueira JV, Meira CS, de Souza SE, de Aragão França LS, Vasconcelos JF, Nonaka CKV, et al. Anti-inflammatory activity of SintMed65, an N-acylhydrazone derivative, in a mouse model of allergic airway inflammation. Int Immunopharmacol. 2019;75: 105735.
Iraji A, Panahi Z, Edraki N, Khoshneviszadeh M, Khoshneviszadeh M. Design, synthesis, in vitro and in silico studies of novel Schiff base derivatives of 2-hydroxy-4-methoxybenzamide as tyrosinase inhibitors. Drug Dev Res. 2021;82(4):533–42.
Hosseinpoor H, Moghadam Farid S, Iraji A, Askari S, Edraki N, Hosseini S, et al. Anti-melanogenesis and anti-tyrosinase properties of aryl-substituted acetamides of phenoxy methyl triazole conjugated with thiosemicarbazide: Design, synthesis and biological evaluations. Bioorg Chem. 2021;114: 104979.
Yazdani M, Edraki N, Badri R, Khoshneviszadeh M, Iraji A, Firuzi O. 5, 6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer’s disease modifying agents. Mol Diversity. 2020;24(3):641–54.
Iraji A, Firuzi O, Khoshneviszadeh M, Nadri H, Edraki N, Miri R. Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer’s disease. Bioorg Chem. 2018;77:223–35.
Shareghi-Boroujeni D, Iraji A, Mojtabavi S, Faramarzi MA, Akbarzadeh T, Saeedi M. Synthesis, in vitro evaluation, and molecular docking studies of novel hydrazineylideneindolinone linked to phenoxymethyl-1,2,3-triazole derivatives as potential α-glucosidase inhibitors. Bioorg Chem. 2021;111: 104869.
Nasli-Esfahani E, Mohammadi-Khanaposhtani M, Rezaei S, Sarrafi Y, Sharafi Z, Samadi N, et al. A new series of Schiff base derivatives bearing 1,2,3-triazole: design, synthesis, molecular docking, and α-glucosidase inhibition. Arch Pharm. 2019;352(8):1900034.
Ansari S, Azizian H, Pedrood K, Yavari A, Mojtabavi S, Faramarzi MA, et al. Design, synthesis, and α-glucosidase-inhibitory activity of phenoxy-biscoumarin–N-phenylacetamide hybrids. Arch Pharm. 2021;354(12):2100179.
Taha M, Shah SAA, Afifi M, Imran S, Sultan S, Rahim F, et al. Synthesis, α-glucosidase inhibition and molecular docking study of coumarin based derivatives. Bioorg Chem. 2018;77:586–92.
Taha M, Ismail NH, Lalani S, Fatmi MQ, Siddiqui S, Khan KM, et al. Synthesis of novel inhibitors of α-glucosidase based on the benzothiazole skeleton containing benzohydrazide moiety and their molecular docking studies. Eur J Med Chem. 2015;92:387–400.
Taha M, Ismail NH, Khan A, Shah SAA, Anwar A, Halim SA, et al. Synthesis of novel derivatives of oxindole, their urease inhibition and molecular docking studies. Bioorg Med Chem Lett. 2015;25(16):3285–9.
Taha M, Ismail NH, Imran S, Selvaraj M, Rahim A, Ali M, et al. Synthesis of novel benzohydrazone–oxadiazole hybrids as β-glucuronidase inhibitors and molecular modeling studies. Bioorg Med Chem. 2015;23(23):7394–404.
Yazdani M, Edraki N, Badri R, Khoshneviszadeh M, Iraji A, Firuzi O. 5,6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer’s disease modifying agents. Mol Divers. 2020;24(3):641–54.
Tao Y, Zhang Y, Cheng Y, Wang Y. Rapid screening and identification of α-glucosidase inhibitors from mulberry leaves using enzyme-immobilized magnetic beads coupled with HPLC/MS and NMR. Biomed Chromatogr. 2013;27(2):148–55.
Sepehri N, Mohammadi-Khanaposhtani M, Asemanipoor N, Hosseini S, Biglar M, Larijani B, et al. Synthesis, characterization, molecular docking, and biological activities of coumarin–1,2,3-triazole-acetamide hybrid derivatives. Arch Pharm. 2020;353(10):2000109.
Iraji A, Shareghi-Brojeni D, Mojtabavi S, Faramarzi MA, Akbarzadeh T, Saeedi M. Cyanoacetohydrazide linked to 1,2,3-triazole derivatives: a new class of α-glucosidase inhibitors. Sci Rep. 2022;12(1):8647.
Karami M, Hasaninejad A, Mahdavi H, Iraji A, Mojtabavi S, Faramarzi Mohammad A, et al. One-pot multi-component synthesis of novel chromeno[4,3-b]pyrrol-3-yl derivatives as alpha-glucosidase inhibitors. Mol Diversity. 2021. https://doi.org/10.1007/s11030-021-10337-w.
Glide V. 5.8; Schrödinger, LLC: New York; 2012. Google Scholar there is no corresponding record for this reference.
Release S. 4: Glide. Schrödinger, LLC, New York, NY; 2018.
Ethics approval and consent to participate
Consent for publication
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. (E)-N'-benzylidene-2,3-diphenylquinoxaline-6-carbohydrazide (7a). Fig. S2. (E)-N'-(2-nitrobenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7b). Fig. S3. (E)-N'-(3-nitrobenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7c). Fig. S4. (E)-N'-(4-nitrobenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7d). Fig. S5. (E)-N'-(3-fluorobenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7e). Fig. S6. (E)-N'-(4-chlorobenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7f). Fig. S7. (E)-N'-(4-methoxybenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7g). Fig. S8. (E)-N'-(3-methoxy-2-nitrobenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7h). Fig. S9. (E)-N'-(2-chloro-5-nitrobenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7i). Fig. S10. (E)-N'-(4-hydroxy-3-methoxybenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7j). Fig. S11. (E)-2,3-diphenyl-N'-(3,4,5-trimethoxybenzylidene)quinoxaline-6-carbohydrazide (7k). Fig. S12. (E)-N'-(3-phenoxybenzylidene)-2,3-diphenylquinoxaline-6-carbohydrazide (7l). Fig. S13. (E)-N'-((6-nitrobenzo[d][1,3]dioxol-5-yl)methylene)-2,3-diphenylquinoxaline-6-carbohydrazide (7m). Fig. S14. (E)-N'-(naphthalen-1-ylmethylene)-2,3-diphenylquinoxaline-6-carbohydrazide (7n). Fig. S15. (E)-2,3-diphenyl-N'-(thiophen-2-ylmethylene)quinoxaline-6-carbohydrazide (7o).
About this article
Cite this article
Pedrood, K., Rezaei, Z., Khavaninzadeh, K. et al. Design, synthesis, and molecular docking studies of diphenylquinoxaline-6-carbohydrazide hybrids as potent α-glucosidase inhibitors. BMC Chemistry 16, 57 (2022). https://doi.org/10.1186/s13065-022-00848-4
- α-glucosidase inhibition
- Type 2 diabetes
- Molecular docking